v3.25.1
Segment Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Information    
Revenue $ 3,120 $ 2,972
Cost of revenue 1,517 1,467
Loss from operations (35,425) (28,801)
Other income (expense), net (2,942) (1,282)
Net loss (38,367) (30,083)
Single reportable segment    
Segment Information    
Revenue 3,120 2,972
Cost of revenue 1,517 1,467
Program expenses 13,177 8,411
Non-program expenses 3,770 6,350
Personnel, including stock-based compensation 20,081 15,545
Loss from operations (35,425) (28,801)
Other income (expense), net (2,942) (1,282)
Net loss (38,367) (30,083)
Single reportable segment | YUTREPIA    
Segment Information    
Program expenses 9,758 6,630
Single reportable segment | L606    
Segment Information    
Program expenses 3,268 1,578
Single reportable segment | Generic Treprostinil    
Segment Information    
Program expenses $ 151 $ 203